Pharma: Other News To Note
Thursday, July 18, 2013
Sihuan Pharmaceutical Holdings Group Ltd., of Hong Kong, said anaprazole sodium, received the approval for clinical studies from the CFDA. Anaprazole sodium is a new generation of proton pump inhibitors (PPIs) for treating ulcers by inhibiting gastric acid secretion and eradicating Helicobacter pylori.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.